Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer.

ABSTRACT:

Introduction

The first generation ligands for prostate-specific membrane antigen (PSMA)-targeted radio- and fluorescence-guided surgery followed by adjuvant photodynamic therapy (PDT) have already shown the potential of this approach. Here, we developed three new photosensitizer-based dual-labeled PSMA ligands by crucial modification of existing PSMA ligand backbone structures (PSMA-1007/PSMA-617) for multimodal imaging and targeted PDT of PCa.

Methods

Various new PSMA ligands were synthesized using solid-phase chemistry and provided with a DOTA chelator for ¹¹¹In labeling and the fluorophore/photosensitizer IRDye700DX. The performance of three new dual-labeled ligands was compared with a previously published first-generation ligand (PSMA-N064) and a control ligan

SUBMITTER: Derks YHW 

PROVIDER: S-EPMC9165289 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature